Prelude Therapeutics Incorporated
PRLD
$4.66
$0.020.43%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 41.00% | 116.67% | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 41.00% | 116.67% | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 41.00% | 116.67% | -- | -- | -- |
| SG&A Expenses | -21.17% | -34.21% | -16.26% | -16.50% | -11.86% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -42.67% | -27.98% | -13.37% | 0.77% | 1.21% |
| Operating Income | 52.56% | 40.60% | 13.37% | -0.77% | 9.49% |
| Income Before Tax | 42.72% | 38.88% | 10.10% | -2.08% | 13.13% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 42.72% | 38.88% | 10.10% | -2.08% | 13.13% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 42.72% | 38.88% | 10.10% | -2.08% | 13.13% |
| EBIT | 52.56% | 40.60% | 13.37% | -0.77% | 9.49% |
| EBITDA | 53.12% | 41.15% | 13.49% | -0.75% | 10.00% |
| EPS Basic | 45.47% | 39.09% | 10.36% | -1.73% | 20.32% |
| Normalized Basic EPS | 49.81% | 39.11% | 10.36% | -1.73% | 20.30% |
| EPS Diluted | 45.47% | 39.09% | 10.36% | -0.52% | 20.32% |
| Normalized Diluted EPS | 49.81% | 39.11% | 10.36% | -1.73% | 20.30% |
| Average Basic Shares Outstanding | 5.06% | 0.36% | 0.31% | 0.33% | 9.02% |
| Average Diluted Shares Outstanding | 5.06% | 0.36% | 0.31% | 0.33% | 9.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |